| Date | Title | Description |
| 01.08.2024 | Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock | VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the stan... |
| 06.03.2024 | Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results | - |
| 05.03.2024 | Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting | - |
| 11.04.2023 | Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more | Mark Adams. (Adaptive Photo)
— Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing.
Adams joined the Seattle-based biotech giant more than three years ago. The fi... |
| 04.02.2022 | Zymeworks : Announces Participation in Upcoming Investor Conferences - Form 8-K | Zymeworks Announces Participation in Upcoming Investor Conferences
Vancouver, Canada and Seattle, Washington (February 03, 2022) - Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherape... |
| 27.01.2022 | Selling shares at a discount, Zymeworks grabs $100M cash in hopes of turnaround | Biotech veteran Kenneth Galbraith got the cash he wants to right the ship at Zymeworks — but not without some compromises.
The Vancouver-based company revealed late Wednesday that it’s raised $100 million in a public offer... |
| 27.01.2022 | Zymeworks Announces Pricing of $100.0 Million Public Offering | Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of common shares to ... |
| 06.01.2022 | Longtime Zymeworks CEO, co-founder Tehrani hits the exit in favor of serial biotech entrepreneur | After a down year, biopharma writ large is looking for a breath of fresh air — and now the winds of change have hit oncology bispecifics player Zymeworks.
Ken Galbraith
Ali Tehrani, a co-founder of Zymeworks who has been the biote... |
| 06.01.2022 | John Maraganore wanted to become a biotech granddad after leaving Alnylam. With his new role at RTW, it looks like he got his wish | On his way out of Alnylam, outgoing CEO John Maraganore, who had led the biotech through thick and thin for 19 years, said late last year he wanted to advise new biotech companies in the grandfather phase of his career.
“It’s lik... |
| 10.11.2021 | Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) - Form 8-K | Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line
HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
• HERIZON-GEA-01 study is now open and enrolling patients to evaluate zanidatamab and chemotherapy with or without tisleli... |
| 26.10.2021 | Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers - Form 8-K | Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Vancouver, British Columbia (October 26, 2021) - Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopha... |
| 13.09.2021 | Zymeworks : Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress (Form 8-K) | Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
• Abstract data demonstrate encouraging antitumor activity in firs... |
| 10.03.2021 | Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 | VANCOUVER, British Columbia--(BUSINESS WIRE)--Mar 10, 2021--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster pre... |
| 27.01.2020 | Zymeworks Announces Closing of US$320.8M Public Offering | VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (“Zymeworks” or the “Company”), announced today the closing of its previously an... |
| 22.01.2020 | Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants | VANCOUVER, British Columbia—(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME) (“Zymeworks” or the “Company”), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplem... |
| 13.01.2020 | Zymeworks Inks Collaboration Agreement with Pfizer in Breast Cancer Study | VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination ther... |
| 22.11.2019 | Zymeworks & BeiGene Advance ZW25 into Potentially Registration-Enabling Global Studies | SINGAPORE — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single-agent ZW25 in heavily pretreated patients with HER2‑expressing soli... |
| 06.11.2019 | BDC spinout Amplitude Ventures closes half of newly-launched $200 million health fund | Amplitude Ventures, a Montréal-headquartered investment firm focused on health and the life sciences sectors has announced the launch of a targeted $200 million CAD venture fund. The firm is a spin-out of the Business Development Bank of Ca... |
| 06.11.2019 | Zymeworks Reports Q3 2019 Financial Results | “We recently presented data on our lead asset, ZW25, at two major medical conferences that pave the way for registration-enabling trials in second-line biliary tract cancer (BTC) with single agent ZW25 and in first-line gastroesophageal ade... |
| 28.10.2019 | Zymeworks Releases Phase 1 Data for ZW25 at International Conference | BOSTON — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announces the first data from its Phase 1 study evaluating novel bispecific antibody ZW25 in combination with ch... |
| 17.10.2019 | Zymeworks Appoints Kathy O’Driscroll to Chief People Officer | VANCOUVER, British Columbia — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the appointment of Kathryn O’Driscoll to the executive team as Chief People Offic... |
| 03.10.2019 | Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at ESMO Congress 2019 | BARCELONA, Spain–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evalua... |
| 17.09.2019 | Lota Zoth Succeeds Nick Bedford as Chair of Zymeworks’ Board of Directors | VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zo... |
| 06.08.2019 | Zymeworks Releases Q2 2019 Financial Results | VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.... |
| 16.07.2019 | Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment | VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has sel... |
| 19.06.2019 | Zymeworks Announces Pricing of $175 million Public Offering | VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the pricing of its previously announced underwritten public... |
| 06.06.2019 | Zymeworks Appoints Accomplished Executives to Board of Directors | VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of two new independent members to its Board... |
| 31.05.2019 | Zymeworks Earns Milestone Payment in Merck Collaboration | VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has earned a milestone payment from Merck (known as... |
| 30.05.2019 | Zymeworks’ Lead Asset, ZW25 Granted Fast Track Designation from FDA | VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track de... |
| 14.05.2019 | Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics | VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants I... |
| 07.05.2019 | Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting | VANCOUVER, Canada–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considere... |
| 03.05.2019 | Zymeworks Reports 2019 First Quarter Financial Results | VANCOUVER, British Columbia–(BUSINESS WIRE) May 2, 2019– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March... |
| 30.04.2019 | Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development | VANCOUVER, British Columbia / BUSINESSWIRE/ Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced it has expanded its leadership team with the hiring of three... |
| 17.01.2019 | Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration | VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new development milestone in its collaboration with Eli L... |
| 19.09.2018 | Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development & Chief Scientific Officer | September 19, 2018 06:45 AM Eastern Daylight Time |
| 04.09.2018 | Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration | Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance wi... |
| 11.06.2018 | Zymeworks Closes Previously Announced Public Offering | VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announ... |
| 24.04.2018 | Sofinnova leads $32.4 million round for Italy's EryDel; Celgene expands collaboration with Zymeworks | → Having followed Milan-based EryDel and its CEO for years, Sofinnova Partners is jumping in for the ride, leading its latest €26.5 million ($32.4 million) round. The funds will cover the registrational Phase III clinical t... |
| 23.04.2018 | Zymeworks and Celgene Expand Bispecific Antibody Collaboration | “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and we are delighted to expand and continue our relationship with them,” said... |
| 04.05.2017 | Zymeworks raises $80 million CAD in IPO | After announcing plans to raise $110 million CAD in an initial public offering (IPO) last week, Vancouver-based Zymeworks announced that it has raised $79.7 million CAD ($58 million USD) in its IPO from the sale of 4.5 million common shares... |
| 01.05.2017 | Term Sheet — Monday, May 1 | STARWOOD-IFICATION OF REAL ESTATE
Increasingly, venture investors view real estate as the next industry to be transformed by disruptive technology. But as they start investing in the category, they might find that traditional real estate in... |
| 25.04.2017 | Zymeworks plans to raise $110 million from its IPO | Vancouver-based Zymeworks plans to raise $110 million from a sale of as many as 5.2 million common shares at $13 USD to $16 USD per unit, according to its recently-updated prospectus.
PE Hub Canada reports that this would give Zymeworks a m... |
| 03.04.2017 | Armed with deals, dollars and the promise of upcoming data, Zymeworks files $75M IPO | Ali Tehrani, Zymeworks accepts@BIOTECanada Gold Leaf award (CREDIT:@biogeniusCA)
A little more than a year ago, as Zymeworks CEO Ali Tehrani was reeling in a $61.5 million crossover round, the biotech CEO told me that he had a two... |
| 08.01.2016 | Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics | Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics
January 08, 2016
Vancouver, Canada – Zymeworks Inc. today announced the closing of a US$ 61.5 million Series... |
| 08.01.2016 | Zymeworks snags huge $61.5 USD million Series A round for its biotherapeutic treatments | Vancouver-based Zymeworks, a biotherapeutics company developing protein therapeutics for the treatment of cancer and autoimmune and inflammatory diseases, announced that it has raised a $61.5 million USD Series A.
The funding was led by bot... |
| 08.01.2016 | Daily funding roundup - January 8, 2016 | MyMusicTaste landed $10M; Zymeworks bagged $61.5M; Pierian closed a $9.25M funding
Blinkist, a Germany-based startup that gives you the gist of well-known nonfiction books in 15 minutes or less, has raised €4 million ($4.3 million) to accel... |
| 08.01.2016 | Zymeworks Closes US$ 61.5M Series A Mezzanine Financing | Zymeworks Inc., a Vancouver, BC, Canada-based biotherapeutics company focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations, closed a US$ 61.5m Serie... |
| 21.01.2015 | Celgene, Biotech's Ace Dealmaker, Bets On Canada's Zymeworks | Celgene, the big maker of blood cancer drugs, has gained a reputation for anointing biotech startups before they break out. Now it’s betting on a little Canadian biotech, Zymeworks, with technology for engineering new types of targeted anti... |
| 06.09.2012 | Zymeworks Raises $11.0M in Funding | Zymeworks Inc., a Vancouver, BC, Canada-based biotherapeutics company focused on the development of bi-specific antibody therapeutics and multi-valent protein therapeutics, has raised $11.0m in funding.
The round was led by the Advanced Bio... |
| 06.09.2012 | Zymeworks Completes $11M Financing |
VANCOUVER, CANADA, Privately held biotherapeutics company announced the completion of a common share offering totaling $11.0 million. The financing was led by the Advanced Biotechnologies Venture Fund.
>> Click here for more fundin... |
| 22.09.2011 | Zymeworks Completes $8.1M Round |
Financing consists of a follow-on round of institutional investment by CTI Life Sciences Fund, L.P., as well as a new investment by Advanced Biotechnologies Venture Fund and investments by several existing private shareholders.
>> ... |
| 22.09.2011 | Zymeworks Raises $8.1M | Zymeworks Inc., a Vancouver, BC, Canada-based biotherapeutics company focused on the development of antibody and protein-based therapeutics, completed a $8.1m financing.
Backers include existing investor CTI Life Sciences Fund, L.P. and pri... |
| 29.06.2010 | Zymeworks Closes $3.2M Financing | Zymeworks Inc., a Vancouver (BC), Canada-based biotechnology company focused on the development of innovative antibody-based therapeutics, closed a $3.2m financing.
The round consists of a follow-on institutional investment by CTI Life Scie... |
| - | Zymeworks Reports 2020 Year-End Financial Results | VANCOUVER, Canada--(BUSINESS WIRE)--Feb 24, 2021--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and... |
